Tag: doxorubicin
Avacta Group reports promising early results for Phase 1a study of AVA6000
Avacta Group plc (AIM: AVCT), a leading life sciences company dedicated to developing innovative oncology drugs and powerful diagnostics, has announced a crucial milestone in ... Read More
Avacta Group progresses to final cohort in Phase 1a study of AVA6000
Avacta Group plc (AIM: AVCT), a leader in the life sciences sector specializing in innovative oncology drugs and diagnostics, has announced the completion of its ... Read More